During a Jan. 29 webinar hosted by the American Medical Association, Dr. Marks said the agency would work to “get these variants covered as quickly as possible.”
Dr. Marks also said updated COVID-19 vaccines would not have to complete another phase 3 trial to ensure efficacy. Rather, they will be required to go through “some small clinical trials” to ensure they incite an immune response and protect against both the new variants and earlier versions of the novel coronavirus.
Experts have not reached a consensus on whether updated vaccines are necessary, but the possibility is being pursued, as B.1.351, the variant first identified in South Africa, has shown it diminishes the effects of COVID-19 vaccines to varying extents.
Vaccines using the mRNA platform, like the ones developed by Moderna and Pfizer, are relatively easy to update for protection against new virus variants. However, experts recommend as many people as possible be vaccinated with current vaccines to slow the spread of the virus, which continues to spread and mutate.
More articles on pharmacy:
US COVID-19 vaccinations exceed positive tests for virus, Bloomberg reports
No need to ration COVID-19 vaccine doses, Biden coronavirus team says
J&J vaccine helpful despite lower efficacy rate, Fauci says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
